34th Annual Miami Breast Cancer Conference®
Thu, 9 Mar 2017, 12:50
Sun, 12 Mar 2017, 01:00
OverviewThe optimal care of patients with breast cancer is rapidly changing as a result of advances in all aspects of patient care, including prevention, screening, and detection, as well as in the primary treatment modalities of surgery, radiation therapy, endocrine therapy, cytotoxic chemotherapy, and novel biologic therapies. There is an increasing focus on providing multidisciplinary care for patients with complex diseases such as breast cancer through the use of integrated teams of professionals representing the relevant treatment modalities, including surgery, radiation therapy, and systemic medical interventions. The multidisciplinary Miami Breast Cancer Conference® has been bringing together surgical, medical, and radiation oncologists, with the aim of fostering awareness of the state-of-the-art treatments in each therapeutic area and encouraging crossteam cooperation in the clinic. At Miami Breast Cancer Conference®, pioneers of innovative approaches in each of these subspecialties will provide insight into the optimal multidisciplinary management of patients with breast cancer and its application to practice.
2017 Can’t-Miss Topics
- Updates in immunology and immunotherapy
- The latest updates and controversies in systemic therapy, including:
- State-of-the-art therapy for early-stage disease
- Anthracycline-sparing approaches for HER2+ breast cancer
- Optimized therapeutic strategies across the disease continuum
- What constitutes a true HER2+ test result?
- Targeted therapies (eg, CDK4/6 inhibition, PARP inhibition, HER2-negative, and androgen receptor targeted agents)
- Novel and emerging therapies and biological paradigms
- Overcoming therapeutic resistance
- Endocrine blockade for ductal carcinoma in situ
- Assessing and reducing breast cancer risk, including:
- What are the clinical utilities of the 70-gene versus the 21-gene and other breast cancer recurrence assays?
- Should biologic factors be incorporated into breast cancer staging?
- How should we choose multiparameter genomic assays in early-stage breast cancer?
- Germline mutation testing update
- Delivery of cancer genetic services
- Critical evaluation of contemporary surgical approaches, including:
- Is the TRAM flap dead?
- Prepectoral technique in breast reconstruction
- Optimized approaches toward breast-conserving therapy, axillary dissection, and surgical margins
- Oncoplastic surgery
- Opioid-sparing pain management strategies
- Standards of care and controversies in radiation therapy (RT), including:
- Postmastectomy RT in patients with 1-3 nodes
- Extended-field RT
- New frontiers in cancer imaging, diagnostics, and treatment, including:
- Radiomics and radiogenomics
- Where are we with circulating tumor cells and cell-free DNA?
- Preoperative MRI in breast-conserving therapy
- Is tomosynthesis mammography ready for prime time?
- New technologies for diagnosis and management of breast-cancer‒associated cardiomyopathy
- Cellular-based therapy for anthracycline-induced cardiomyopathy
- Novel treatment options for chemotherapy-induced cardiomyopathy
- Sexuality and fertility
- Practice management, including:
- The doctor‒patient relationship in the era of precision medicine
- Is breast surgical oncology a dying specialty?
- What does the future hold for academic medical centers versus academic medical systems?
- How will the Medicare Access and CHIP Reauthorization Act (MACRA) affect breast cancer practice?
- Value comparison of local therapy treatment approaches in early-stage breast cancer
Target AudienceThis educational program is directed toward medical, surgical, and radiation oncologists interested in the treatment of patients with breast cancer. Fellows, nurse practitioners, nurses, physician assistants, researchers, and other health care professionals interested in the treatment of breast cancer are also invited to attend.
Mini Symposium* &
March 9 - 12, 2017
Main Conference Only
March 10 - 12, 2017
|Nurses, PAs, Other Health Care Professionals|
|Guest (access to receptions only)*|
*Discount does not apply to the Mini-Symposium or Guest Registration.
**FELLOWS registration must be accompanied by a letter from your director/chair stating current fellowship for discount.
***INDUSTRY is defined by PER® as any person employed by a for-profit organization, including biotech, financial, and pharmaceutical.
Wed, 17 Jan 2018 - Fri, 19 Jan 2018
Mon, 29 Jan 2018 - Thu, 1 Feb 2018
Mon, 5 Feb 2018 - Thu, 8 Feb 2018
United Arab Emirates
Wed, 7 Feb 2018 - Thu, 8 Feb 2018
Thu, 15 Feb 2018 - Thu, 15 Feb 2018
Stockholms län 113 22
Thu, 1 Mar 2018 - Sat, 3 Mar 2018
Thu, 15 Mar 2018 - Sat, 17 Mar 2018